Nazanin Hajarol Asvadi1, Sohrab Afshari Mirak2, Amirhossein Mohammadian Bajgiran1, Pooria Khoshnoodi1, Pornphan Wibulpolprasert3, Daniel Margolis4, Anthony Sisk5, Robert E Reiter6, Steven S Raman1,6. 1. Department of Radiological Sciences, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. 2. Department of Radiological Sciences, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. safsharimirak@ucla.edu. 3. Department of Radiology, Ramathibodi Hospital, Bangkok, Thailand. 4. Department of Radiology, Weill Cornell Imaging, NewYork-Presbyterian, New York, NY, USA. 5. Department of Pathology, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. 6. Department of Urology, David Geffen School of Medicine at UCLA, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
Abstract
PURPOSE: To evaluate 3T mpMRI characteristics of transition zone and peripheral zone index prostate cancer lesions stratified by Gleason Score and PI-RADSv2 with whole mount histopathology correlation. METHODS: An institution review board-approved, HIPAA-compliant single-arm observational study of 425 consecutive men with 3T mpMRI prior to radical prostatectomy from December 2009 to October 2016 was performed. A genitourinary radiologist and a genitourinary pathologist matched all lesions detected on whole mount histopathology with lesions concordant for size and location on 3T mpMRI. Differences in clinical, MRI parameters, and histopathology between transition zone and peripheral zone were determined and analyzed with χ2 and Mann-Whitney U test. AUC was measured. RESULTS: 3T mpMRI detected 248/323 (76.7%) index lesions in peripheral zone and 75/323 (23.2%) in transition zone. Transition zone prostate cancer had higher median prostate-specific antigen (p = 0.001), larger tumor on 3T mpMRI (p = 0.001), lower proportions of PI-RADSv2 category 4 and 5 (p < 0.001), and lower pathological stage (p = 0.055) compared to peripheral zone prostate cancer. No significant differences were detected in prostate-specific antigen density, preoperative biopsy, and pathology Gleason Scores. After adjusting for significant variables from univariate analysis including prostate volume, tumor volume, prostate-specific antigen, PI-RADSv2 category, AUC for predicting clinically significant tumor in transition zone and peripheral zone were 0.80 and 0.72, respectively (p = 0.36). CONCLUSIONS: The diagnostic performance of PI-RADSv2 for clinically significant transition and peripheral zone prostate cancer was similar. However, there was a lower portion of PI-RADSv2 4 and 5 lesions in transition zone compared to peripheral zone.
PURPOSE: To evaluate 3T mpMRI characteristics of transition zone and peripheral zone index prostate cancer lesions stratified by Gleason Score and PI-RADSv2 with whole mount histopathology correlation. METHODS: An institution review board-approved, HIPAA-compliant single-arm observational study of 425 consecutive men with 3T mpMRI prior to radical prostatectomy from December 2009 to October 2016 was performed. A genitourinary radiologist and a genitourinary pathologist matched all lesions detected on whole mount histopathology with lesions concordant for size and location on 3T mpMRI. Differences in clinical, MRI parameters, and histopathology between transition zone and peripheral zone were determined and analyzed with χ2 and Mann-Whitney U test. AUC was measured. RESULTS: 3T mpMRI detected 248/323 (76.7%) index lesions in peripheral zone and 75/323 (23.2%) in transition zone. Transition zone prostate cancer had higher median prostate-specific antigen (p = 0.001), larger tumor on 3T mpMRI (p = 0.001), lower proportions of PI-RADSv2 category 4 and 5 (p < 0.001), and lower pathological stage (p = 0.055) compared to peripheral zone prostate cancer. No significant differences were detected in prostate-specific antigen density, preoperative biopsy, and pathology Gleason Scores. After adjusting for significant variables from univariate analysis including prostate volume, tumor volume, prostate-specific antigen, PI-RADSv2 category, AUC for predicting clinically significant tumor in transition zone and peripheral zone were 0.80 and 0.72, respectively (p = 0.36). CONCLUSIONS: The diagnostic performance of PI-RADSv2 for clinically significant transition and peripheral zone prostate cancer was similar. However, there was a lower portion of PI-RADSv2 4 and 5 lesions in transition zone compared to peripheral zone.
Entities:
Keywords:
Gleason score; Multiparametric magnetic resonance imaging; PI-RADSv2; Prostate cancer
Authors: Nicolas Barry Delongchamps; Mathieu Rouanne; Thierry Flam; Frédéric Beuvon; Mathieu Liberatore; Marc Zerbib; François Cornud Journal: BJU Int Date: 2010-11-02 Impact factor: 5.588
Authors: Jesse D Le; Nelly Tan; Eugene Shkolyar; David Y Lu; Lorna Kwan; Leonard S Marks; Jiaoti Huang; Daniel J A Margolis; Steven S Raman; Robert E Reiter Journal: Eur Urol Date: 2014-09-23 Impact factor: 20.096
Authors: Andrew B Rosenkrantz; Luke A Ginocchio; Daniel Cornfeld; Adam T Froemming; Rajan T Gupta; Baris Turkbey; Antonio C Westphalen; James S Babb; Daniel J Margolis Journal: Radiology Date: 2016-04-01 Impact factor: 11.105
Authors: Eline K Vos; Thiele Kobus; Geert J S Litjens; Thomas Hambrock; Christina A Hulsbergen-van de Kaa; Jelle O Barentsz; Marnix C Maas; Tom W J Scheenen Journal: Invest Radiol Date: 2015-08 Impact factor: 6.016
Authors: Nelly Tan; Wei-Chan Lin; Pooria Khoshnoodi; Nazanin H Asvadi; Jeffrey Yoshida; Daniel J A Margolis; David S K Lu; Holden Wu; Kyung Hyun Sung; David Y Lu; Jaioti Huang; Steven S Raman Journal: Radiology Date: 2016-11-18 Impact factor: 11.105
Authors: Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey Journal: Radiology Date: 2015-06-18 Impact factor: 11.105
Authors: J Joy Lee; I-Chun Thomas; Rosalie Nolley; Michelle Ferrari; James D Brooks; John T Leppert Journal: Prostate Date: 2014-10-18 Impact factor: 4.104
Authors: Joaquin J Garcia; Hikmat A Al-Ahmadie; Anuradha Gopalan; Satish K Tickoo; Peter T Scardino; Victor E Reuter; Samson W Fine Journal: Am J Surg Pathol Date: 2008-11 Impact factor: 6.394
Authors: Marc R Engelbrecht; Henkjan J Huisman; Robert J F Laheij; Gerrit J Jager; Geert J L H van Leenders; Christina A Hulsbergen-Van De Kaa; Jean J M C H de la Rosette; Johan G Blickman; Jelle O Barentsz Journal: Radiology Date: 2003-08-27 Impact factor: 11.105